Lethal synergy involving bicyclomycin: An approach for reviving old antibiotics

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 12, 2014, Pages 3227-3235

  Malik, Muhammad ^a   Li, Liping ^a   Zhao, Xilin ^a,b   Kerns, Robert J ^c   Berger, James M ^d,e   Drlica, Karl ^a,b  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acinetobacter baumannii; Back tracking; Escherichia coli; Gene expression inhibitors; Klebsiella pneumoniae; Transcription elongation complex

Indexed keywords

BICOZAMYCIN; CHLORAMPHENICOL; RIFAMPICIN; TETRACYCLINE; ANTIINFECTIVE AGENT; FUSED HETEROCYCLIC RINGS;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ESCHERICHIA COLI; GENE EXPRESSION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SHIGELLA DYSENTERIAE; TRANSCRIPTION ELONGATION; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; DRUG SYNERGISM; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY;

EID: 84916913846     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku285     Document Type: Article

References (25)

1. Stratton C. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003; 9: 10-6.
2. Eliopoulos G, Moellering R. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Philadelphia, PA, USA: William & Wilkins Co., 1996.
3. Meletiadis J, Pournaras S, Roilides E et al. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitroin vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother 2010; 54: 602-9.
4. Skordalakes E, Brogan A, Park B et al. Structural mechanismof inhibition of the Rho transcription termination factor by the antibiotic bicyclomycin. Structure 2005; 13: 99-109.
5. Zwiefka A, Kohn H, Widger W. Transcription termination factor rho: the site of bicyclomycin inhibition in Escherichia coli. Biochemistry 1993; 32: 3564-70.
6. Moyse K, Knight J, Richardson J. Phenotypic characterization of a comprehensive set of bicyclomycin-resistant mutants. Biochim Biophys Acta 2001; 1520: 223-33.
7. Dutta D, Shatalin K, Epshtein V et al. Linking RNA polymerase backtracking to genome instability in E. coli. Cell 2011; 146: 533-43.
8. Washburn R, Gottesman M. Transcription termination maintains chromosome integrity. Proc Natl Acad Sci USA 2011; 108: 792-7.
9. Nishida M, Mine Y, Matsubara T. Bicyclomycin, an new antibiotic III. in vitro and in vivo antimicrobial activity. J. Antibiot (Tokyo) 1972; 25: 582-93.
10. Tran L, VanBaarsel J, Washburn R et al. Single-gene deletion mutants of Escherichia coli with altered sensitivity to bicyclomycin, an inhibitor of transcription termination factor Rho. J Bacteriol 2011; 193: 2229-35.
11. Miller J. Experiments in Molecular Genetics. Cold Spring Harbor, NY, USA: Cold Spring Harbor Laboratory Press, 1972.
12. MalikM, Zhao X, DrlicaK. Lethal fragmentationofbacterial chromosomes mediated by DNA gyrase and quinolones. Mol Microbiol 2006; 61: 810-25.
13. Moyse K, Knight J, Richardson J. The bicyclomycin sensitivities of 38 bicyclomycin-resistant mutants of transcription termination protein rho and the location of their mutations support a structural model of rho based on the F1 ATPase. J Mol Biol 2000; 302: 565-79.
14. Krasin F, Hutchinson F. Repair of DNA double-strand breaks in Escherichia coli, which requires recA function and the presence of a duplicate genome. J Mol Biol 1977; 116: 81-98.
15. Cardinale CJ, Washburn RS, Tadigotla VR et al. Termination factor Rho and its cofactors NusA and NusG silence foreign DNA in E. coli. Science 2008; 320: 935-8.
16. Wang X, Kim Y, Ma Q et al. Cryptic prophages help bacteria cope with adverse environments. Nat Commun 2010; 1: 147.
17. Conter A, Bouché J, Dassain M. Identification of a new inhibitor of essential division gene ftsZ as the kil gene of defective prophage Rac. J Bacteriol 1996; 178: 5100-4.
18. Fassler J, Tessman I, Tessman E. Lethality of the double mutations rho rep and rho ssb in Escherichia coli. J Bacteriol 1985; 161: 609-14.
19. Pósfai G, Plunkett G 3rd, Fehér T et al. Emergent properties of reduced-genome Escherichia coli. Science 2006; 312: 1044-6.
20. Nishida M, Mine Y, Matusbara T et al. Bicyclomycin, a new antibiotic. IV. Absorption, excretion and tissue distribution. J Antibiotics 1972; 25: 594-601.
21. Ericsson C, DuPont HL, Sullivan P et al. Bicozamycin, a poorly absorbable antibiotic, effectively treats travelers' diarrhea. Ann Intern Med 1983; 98: 20-5.
22. Miyoshi T, Miyairi N, Aoki H et al. Bicyclomycin, a new antibiotic. I. Taxonomy, isolation and characterization. J Antibiotics 1972; 25: 569-75.
23. Park B, Widger W, Kohn H. Fluorine-substituted dihydrobicyclomycins: synthesis and biochemical and biological properties. Bioorg Med Chem 2006; 14: 41-61.
24. Scott J. Genetic studies on bacteriophage P1. Virology 1968; 6: 564-74.
25. Malik M, Hoatam G, Chavda K et al. Novel approach for comparing abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure. Antimicrob Agents Chemother 2010; 54: 149-56.